Heights Capital Management’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
Other funds holding GRCE
Heights Capital Management's GRCE Position: Q2 2019 in Review
Heights Capital Management sold out of Grace Therapeutics (GRCE) in Q2 2019, closing a stake of 1,281 shares — an estimated $63K sold.
Heights Capital Management first reported a position in GRCE in Q1 2019 and held it in 1 quarter. The position peaked at $63K in Q1 2019. 13 funds tracked by Wall St. Rank hold GRCE as of Q2 2019.
- Heights Capital Management reported no remaining Grace Therapeutics position as of Q2 2019 after selling out during the quarter.
- Heights Capital Management sold 1,281 Grace Therapeutics shares in Q2 2019, an estimated $63K.
- Heights Capital Management first reported a position in Grace Therapeutics in Q1 2019 and held it in 1 quarter.
- Heights Capital Management's Grace Therapeutics position peaked at $63K in Q1 2019.
- 13 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2019.
Based on Heights Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.